Dealogic and ITG Collaborate on Complete Buyside Solution
5.7.2017 15:00 | Business Wire
Financial platform company Dealogic announced a collaboration with ITG, a leading independent broker and financial technology provider.
With this arrangement, asset managers who use Dealogic Connect for reconciliation and evaluation of bank activities will have seamless access to the ITG Research Payment Account (RPA). This allows European asset managers to fund their RPAs with a research charge alongside the execution, in a manner that can be operationally similar to a traditional Commission Sharing Agreement (CSA). RPA accounts managed by ITG are held in a bank account at a major global bank in Europe, segregated from brokers’ funds, administered by ITG and controlled by the asset manager.
“This is just another proof point that Dealogic Connect offers an easy and comprehensive solution for buyside firms,” noted Jody Drulard, Dealogic’s Chief Product Officer. “We know commission management is top-of-mind, by collaborating with ITG we ensure firms can use whatever provider they want.”
Jack Pollina, ITG’s Global Head of Commission Management, commented, “With the MiFID II implementation date quickly approaching, asset managers will need global partners to provide end-to-end solutions. Working together with Dealogic enables us to provide clients with the tools they need to address the compliance and reporting challenges that lie ahead.”
Dealogic Connect offers a seamless electronic connection between the buyside and sellside. Investment firms can reconcile and evaluate all bank-provided activities, ensuring a complete audit trail satisfying MiFID II regulatory needs, as well as input IOIs to their brokers on primary markets issuance.
Dealogic offers integrated content, analytics, and technology via targeted products and services to financial firms worldwide. Whether working in capital markets, sales and trading, banking, or the buyside, firms rely on Dealogic’s platform to connect and more effectively identify opportunities, execute deals, and manage risk. With 30 years’ experience and a deep understanding of financial markets, Dealogic is a trusted global partner. For more information on Dealogic, visit www.dealogic.com
Investment Technology Group applies technology and trading expertise to reduce implementation costs, helping clients improve investment performance. ITG is a leading provider of commission management services including research payment and budget capabilities and offers both traditional CSA and aggregation services worldwide as well as RPA administration services for asset managers with registered operations in Europe. ITG provides access to a network of more than 5,000 research providers, brokers and vendors worldwide. ITG’s commission management team of more than 30 experienced client service, ﬁnance and operations professionals in Europe, North America and Asia Paciﬁc, are dedicated to guiding clients in their global RPA management. ITG was ranked #1 for CSA service and execution quality among mutual funds and hedge funds in the 2016 Greenwich Associates U.S. survey. For more information, visit www.itg.com.
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
XILAM Successfully Completes €15m Bond Issue on Euro PP Market27.7.2017 17:42 | Pressemelding
Regulatory News: Xilam (Paris:XIL) today announced the completion of its Euro PP bond issue. The €15 million private placement, repayable at maturity, was subscribed by the NOVI 2 fund managed by Idinvest Partners on behalf of institutional investors and by a European insurer. The bonds have a 6-year maturity, and will be issued in two tranches: The first tranche will be at a variable rate of 6-month EURIBOR* + 400 bp The second tranche will be at a fixed rate of 3.5%. Favourable terms were obtained for the issue with successive drawdown options (limited to 18 months), which will allow the company to optimise the cost of its debt according to its needs. Xilam was advised on the transaction by Euroland Corporate. “We are delighted to have successfully completed this financing transacti
SFL – First-Half 2017 Results27.7.2017 17:00 | Pressemelding
Regulatory News: The interim consolidated financial statements for the six months ended 30 June 2017 were approved by the Board of Directors of Société Foncière Lyonnaise (Paris:FLY) on 27 July 2017, at a meeting chaired by Juan-Jose Brugera. First-half business indicators were robust, thanks to the high portfolio occupancy rate, while the period also saw gains in the portfolio's appraisal value and the Company's net asset value. The auditors have completed their review of the interim financial statements. Consolidated data (€ millions)
Boehringer Ingelheim starts clinical study on interchangeability between its adalimumab biosimilar candidate and HUMIRA®27.7.2017 13:00 | Pressemelding
Boehringer Ingelheim announced today that the first patient has been enrolled into its VOLTAIRE-X interchangeability study. The goal of the study is to demonstrate that BI 695501 is interchangeable with the U.S.-marketed formulation of Humira®* 40mg/0.8mL. This is the first study in the U.S. to investigate an interchangeability designation for an adalimumab biosimilar candidate. The study will compare the pharmacokinetics and clinical outcomes between patients receiving Humira® continuously, versus those who switch repeatedly between Humira® and BI 695501, Boehringer Ingelheim’s adalimumab biosimilar candidate.1 The study will also assess safety, immunogenicity and efficacy.1 “We are pleased that the first patient has now been enrolled in VOLTAIRE-X, and look forward to continued recruitment and patient follow-up,” said Ivan Blanarik, Senior Vice President and Head of
Acxiom Launches Connected Spaces27.7.2017 12:30 | Pressemelding
Today, Acxiom® (Nasdaq: ACXM), in collaboration with Adobe, announced the launch of Connected Spaces, a global solution aimed at delivering more relevant omnichannel experiences to customers. Connected Spaces is designed to revolutionise customer experience and business returns for retail, travel and leisure locations such as airports, malls, sports stadiums, concert arenas and resorts. A pioneering example is Heathrow airport. Heathrow is able to deliver more relevant communications to customers in real-time as part of its overall engagement strategy and is already generating exceptional results including an increase in spend of 20-25 percent for engaged customers. Common to airports, malls and the like is a high footfall of consumers who intend to visit multiple concession, franchise, or subcontracted brands operating in their environments. This can translate to a relative
Watch BizWireTV: Helix Brings DNA Kits to the Public and Michael Kors Gets Ready to Buy Jimmy Choo27.7.2017 12:08 | Pressemelding
On the latest BizWireTV, catch the latest Quick Biz Hits. Also see what’s happening in the startup world with the Accelerator Report, featuring the VC Watch and this week’s Startup Standout. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170727005456/en/ BizWireTV is hosted by Jordyn Rolling (Photo: Business Wire) Now you can watch BizWireTV, and the latest breakthroughs in tech from the biggest brands, on any screen you want by downloading the new app through the Apple TV and iPhone App Store and Google Play for Android devices. Top of the Wire Helix launches first online consumer marketplace for DNA-powered products that offer insights on ancestry, entertainment, family, fitness, health and nutrition. Watch BizWireTV to
European Commission Grants Orphan Drug Designation to Allena Pharmaceuticals’ Investigational Therapy for the Treatment of Primary Hyperoxaluria27.7.2017 11:05 | Pressemelding
Allena Pharmaceuticals, Inc., a specialty biopharmaceutical company dedicated to bringing first in class, specific, non-absorbed, oral enzyme therapeutics to patients with serious renal, urologic and orphan diseases, announced today that the European Commission has granted orphan drug designation to Allena’s investigational product ALLN-177, Bacillus subtilis oxalate decarboxylase, for the treatment of primary hyperoxaluria (PH). The orphan designation was granted to Allena Pharmaceuticals Ireland Limited, a subsidiary of Allena Pharmaceuticals, Inc. Allena’s lead compound ALLN-177, is being developed to treat patients with severe hyperoxaluria, a condition characterized by markedly elevated urinary oxalate excretion. PH, a type of severe hyperoxaluria, is a rare genetic disorder caused by endogenous overproduction of oxalate by the liver that can result in kidney stone disease, kidney
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom